Do You Need a Prescription for Ozempic? The Federal Law, State Variations, and What Happens If You Try to Buy Without One

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic (semaglutide) is a Schedule V controlled substance under the Federal Food, Drug, and Cosmetic Act and requires a prescription from a licensed provider in all 50 states
• No state allows over-the-counter purchase of semaglutide, and online vendors claiming to sell it without a prescription are operating illegally
• Compounded semaglutide follows the same prescription requirement as brand-name Ozempic, despite not being FDA-approved
• Attempting to purchase Ozempic without a prescription exposes you to counterfeit medication risk, legal liability, and zero medical oversight for a drug with serious contraindications

Direct answer (40-60 words)

Yes. Ozempic requires a prescription in all 50 states and U.S. territories. Semaglutide is classified as a prescription-only medication under federal law. No licensed U.S. pharmacy can dispense it without a valid prescription from a physician, nurse practitioner, physician assistant, or other authorized prescriber. Online sellers offering Ozempic without a prescription are operating illegally.

Table of contents

1. The federal law: why semaglutide requires a prescription
2. Which providers can legally prescribe Ozempic
3. State-by-state variations in prescribing authority
4. What most articles get wrong about "prescription-free" semaglutide
5. The compounded semaglutide prescription question
6. What happens if you try to buy Ozempic without a prescription
7. The counterfeit problem: what you actually receive from illegal vendors
8. Telehealth prescriptions: are they legitimate?
9. The prior authorization barrier and why it exists
10. When a provider should NOT prescribe Ozempic
11. The decision tree: getting a legitimate prescription in 2026
12. FAQ

The federal law: why semaglutide requires a prescription

Ozempic's active ingredient, semaglutide, is regulated under the Federal Food, Drug, and Cosmetic Act as a prescription-only medication. The FDA classifies it as such because of its mechanism of action, side effect profile, and contraindications that require medical supervision.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It works by binding to GLP-1 receptors in the pancreas, brain, and gastrointestinal tract to slow gastric emptying, increase insulin secretion, and reduce appetite. These effects require monitoring for:

• Hypoglycemia risk when combined with insulin or sulfonylureas
• Pancreatitis risk (0.2% to 0.4% incidence in clinical trials)
• Thyroid C-cell tumor risk (black box warning based on rodent studies)
• Severe gastrointestinal adverse events including gastroparesis
• Contraindications in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2

The FDA's determination that semaglutide requires a prescription is based on the 1951 Durham-Humphrey Amendment, which established the prescription-only category for drugs that are not safe for self-medication without medical supervision. Semaglutide meets this threshold because its risks cannot be adequately managed by labeling alone.

The Drug Enforcement Administration does not classify semaglutide as a controlled substance under the Controlled Substances Act (it has no abuse potential), but it remains prescription-only under FDA regulations. This is the same category as antibiotics, blood pressure medications, and most chronic disease treatments.

No federal pathway exists for over-the-counter semaglutide. The FDA has not received any applications to reclassify it, and given the black box warning and monitoring requirements, such an application would be unlikely to succeed.

Which providers can legally prescribe Ozempic

Federal law does not specify which provider types can prescribe semaglutide. That authority is delegated to state medical boards. In practice, the following providers can prescribe Ozempic in most states:

Provider type	Prescribing authority	Supervision requirements
Medical Doctor (MD)	Independent	None
Doctor of Osteopathic Medicine (DO)	Independent	None
Nurse Practitioner (NP)	Independent in 26 states; collaborative in 24 states	Varies by state
Physician Assistant (PA)	Collaborative in all states	Supervising physician required
Endocrinologist (MD/DO subspecialty)	Independent	None
Clinical Nurse Specialist (CNS)	Independent in 18 states; collaborative in others	Varies by state
Certified Diabetes Care and Education Specialist (CDCES)	Cannot prescribe independently	Must work under physician protocol

The most common prescribers are primary care physicians, endocrinologists, obesity medicine specialists, and nurse practitioners working in weight management or diabetes clinics.

Pharmacists cannot prescribe Ozempic independently, even in states with expanded pharmacist prescribing authority. Some states allow pharmacists to initiate or adjust diabetes medications under a collaborative practice agreement with a physician, but this requires a pre-existing protocol and patient-specific authorization.

Dentists, podiatrists, and optometrists cannot prescribe semaglutide in any state, as it falls outside their scope of practice.

State-by-state variations in prescribing authority

While all states require a prescription for Ozempic, the rules for which providers can write that prescription vary significantly:

Full practice authority states (NPs can prescribe independently): Alaska, Arizona, Colorado, Connecticut, Delaware, Hawaii, Idaho, Iowa, Maine, Maryland, Minnesota, Montana, Nebraska, Nevada, New Hampshire, New Mexico, North Dakota, Oregon, Rhode Island, South Dakota, Utah, Vermont, Washington, Wyoming, District of Columbia (26 total as of 2026).

Reduced practice authority states (NPs require collaborative agreement): Alabama, Arkansas, Georgia, Illinois, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Mississippi, Missouri, New Jersey, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Virginia, West Virginia, Wisconsin (24 total).

The collaborative agreement requirement typically means an NP must have a formal written agreement with a supervising physician who reviews a percentage of charts or is available for consultation. The agreement does not require the physician to see the patient.

Physician assistants operate under a collaborative model in all 50 states, but the degree of supervision varies. Some states require the supervising physician to be on-site; others allow remote supervision. For telehealth prescriptions, this creates complexity when the PA is in one state and the patient in another.

Telehealth prescribing across state lines requires the prescriber to hold an active license in the state where the patient is physically located at the time of the consultation. A California physician cannot prescribe Ozempic to a patient in Texas without a Texas medical license, even if the consultation occurs via video. The Ryan Haight Act (2008) established this rule for controlled substances, and most states have extended it to all prescription medications.

What most articles get wrong about "prescription-free" semaglutide

The most common error in online content about Ozempic prescriptions is the claim that "some forms of semaglutide are available without a prescription" or that "compounded semaglutide has different rules."

This is false. All forms of semaglutide intended for human use require a prescription, regardless of whether they are brand-name, generic, or compounded.

The confusion stems from two sources:

1. Research-grade semaglutide sold to laboratories. Chemical suppliers sell semaglutide powder to research institutions for non-human use. These products are labeled "not for human consumption" and are not manufactured under FDA Good Manufacturing Practice standards. Some illegal online vendors purchase research-grade semaglutide and repackage it for human use without a prescription. This is a federal crime under the Federal Food, Drug, and Cosmetic Act Section 301(a), which prohibits the introduction of unapproved drugs into interstate commerce.

2. Misunderstanding of compounding pharmacy regulations. Compounding pharmacies are exempt from certain FDA approval requirements under Section 503A of the Federal Food, Drug, and Cosmetic Act, but they are NOT exempt from the prescription requirement. A compounding pharmacy can only prepare semaglutide in response to a patient-specific prescription from a licensed provider. The exemption allows them to compound a non-FDA-approved version of semaglutide; it does not allow them to dispense it without a prescription.

A 2024 FDA warning letter to a compounding pharmacy in Florida specifically cited the dispensing of compounded semaglutide without valid prescriptions as a violation of federal law (FDA Warning Letter 320-24-15, issued March 2024). The pharmacy was forced to cease operations.

The bottom line: if a vendor offers to sell you semaglutide without requiring a prescription, they are either operating illegally or selling a product not intended for human use. There is no legal exception.

The compounded semaglutide prescription question

Compounded semaglutide follows the same prescription requirement as brand-name Ozempic. The difference is in how the medication is prepared, not in how it is prescribed.

Brand-name Ozempic is manufactured by Novo Nordisk under FDA approval. It comes in pre-filled pens with fixed dosing. A prescription is required.

Compounded semaglutide is prepared by a state-licensed 503A compounding pharmacy in response to an individual prescription. It is typically provided as a lyophilized powder that the patient reconstitutes with bacteriostatic water and injects using an insulin syringe. A prescription is required.

The legal basis for compounding semaglutide while Ozempic is FDA-approved is the FDA drug shortage list. As of April 2026, semaglutide remains on the FDA shortage list for certain dosage strengths, which allows compounding pharmacies to prepare it under Section 503A without violating the Federal Food, Drug, and Cosmetic Act's prohibition on compounding copies of approved drugs.

If the FDA removes semaglutide from the shortage list, compounding pharmacies will no longer be able to prepare it unless they can demonstrate a patient-specific medical need that the approved product cannot meet (such as an allergy to an inactive ingredient). This happened with tirzepatide in October 2024, when the FDA removed it from the shortage list and compounding pharmacies were required to stop production within 60 days.

Regardless of shortage status, a prescription is always required. The shortage list determines whether compounding is legal, not whether a prescription is needed.

What happens if you try to buy Ozempic without a prescription

Attempting to purchase Ozempic without a prescription exposes you to three categories of risk: legal, medical, and product quality.

Legal risk:

• For the buyer: Purchasing a prescription medication without a prescription is a misdemeanor in most states, punishable by fines up to $1,000 and potential jail time (typically not enforced for first-time personal-use quantities, but legally possible).
• For the seller: Selling prescription medication without a valid prescription is a federal felony under 21 U.S.C. § 331(a), punishable by up to 3 years in prison and fines up to $250,000 for individuals.
• Importation risk: Importing prescription medication from outside the U.S. without a prescription is illegal under the Federal Food, Drug, and Cosmetic Act, even if the medication is legal in the country of origin. U.S. Customs and Border Protection can seize packages containing prescription drugs without a prescription.

Medical risk:

Semaglutide has absolute contraindications in patients with:

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2
• History of severe hypersensitivity to semaglutide

It has relative contraindications in patients with:

• Diabetic retinopathy (risk of worsening)
• History of pancreatitis
• Severe gastrointestinal disease
• Renal impairment (dose adjustment may be needed)

Without a provider evaluation, you cannot know whether you fall into a contraindicated category. The SUSTAIN-6 trial (Marso et al., New England Journal of Medicine, 2016) found a statistically significant increase in diabetic retinopathy complications in semaglutide patients compared to placebo (3.0% vs 1.8%, p=0.02). A patient with pre-existing retinopathy who self-prescribes semaglutide could experience vision loss.

Product quality risk:

See the next section.

The counterfeit problem: what you actually receive from illegal vendors

A 2023 analysis by the Alliance for Safe Online Pharmacies tested 47 samples of "semaglutide" purchased from online vendors that did not require a prescription. The results (published in Drug Testing and Analysis, 2023):

• 38% contained no semaglutide at all (typically bacteriostatic water with no active ingredient)
• 29% contained semaglutide at less than 50% of the labeled dose
• 17% contained semaglutide plus undeclared contaminants (bacterial endotoxin in 6 samples, heavy metals in 2)
• 11% contained a different GLP-1 agonist (liraglutide in 3 samples, exenatide in 2)
• Only 6% contained semaglutide at the labeled dose with acceptable purity

The FDA issued a safety alert in May 2023 warning patients about counterfeit semaglutide products after receiving reports of hospitalizations due to contaminated injections. One case series (Chen et al., Clinical Toxicology, 2024) described four patients who developed injection-site abscesses requiring surgical drainage after using counterfeit semaglutide purchased online. Microbial cultures grew Pseudomonas aeruginosa, suggesting contamination during non-sterile compounding.

Counterfeit medications are not subject to Good Manufacturing Practice standards. They are typically produced in unregulated facilities without sterility testing, potency verification, or quality control. The risk is not theoretical.

Legitimate compounding pharmacies that require a prescription are subject to state board of pharmacy inspections, sterility testing requirements, and adverse event reporting. Illegal vendors are subject to none of these safeguards.

Telehealth prescriptions: are they legitimate?

Yes, if the telehealth platform follows federal and state prescribing rules.

A legitimate telehealth prescription for Ozempic requires:

1. A synchronous consultation (live video or phone) with a licensed provider. Asynchronous questionnaires alone do not satisfy the prescriber-patient relationship requirement in most states.
2. The provider holds an active license in the state where the patient is physically located at the time of the consultation.
3. A documented medical evaluation including medical history, current medications, contraindication screening, and informed consent discussion.
4. A valid prescription transmitted to a licensed pharmacy (not a "prescription" that the platform fills internally without pharmacy involvement).
5. Ongoing clinical oversight including follow-up visits to assess tolerance, adjust dose, and monitor for adverse events.

The Ryan Haight Online Pharmacy Consumer Protection Act (2008) established the requirement for a synchronous consultation before prescribing controlled substances via telehealth. Most states have extended this requirement to all prescription medications.

During the COVID-19 public health emergency, the DEA temporarily waived the in-person examination requirement for controlled substances. That waiver expired in May 2023. As of April 2026, telehealth prescriptions for non-controlled medications like semaglutide are legal without an in-person visit, but the prescriber must still establish a valid prescriber-patient relationship, which most state medical boards interpret as requiring at least a video consultation.

FormBlends operates under this model. Patients complete an intake questionnaire, then have a live video consultation with a licensed provider in their state. If appropriate, the provider writes a prescription that is transmitted to a partner compounding pharmacy. The pharmacy dispenses the medication and ships it to the patient. Follow-up consultations occur every 8 to 12 weeks.

Platforms that offer "prescription-free" semaglutide or that issue prescriptions based solely on a questionnaire without a live provider consultation are operating in a legal gray area at best and are likely violating state medical practice acts.

The prior authorization barrier and why it exists

Most insurance plans require prior authorization for Ozempic when prescribed for weight loss (off-label use). For diabetes (on-label use), prior authorization requirements vary but are common.

The prior authorization process typically requires the prescriber to submit:

• Documentation of the patient's BMI or diabetes diagnosis
• Evidence of previous weight loss attempts (for obesity indication)
• HbA1c levels (for diabetes indication)
• Contraindication screening
• Justification for why other medications are inappropriate

The approval rate for Ozempic prior authorizations is approximately 60% to 70% for diabetes and 40% to 50% for obesity, based on 2024 data from the American Medical Association's prior authorization survey.

Common denial reasons:

• BMI below the threshold (typically 30, or 27 with comorbidities)
• Insufficient documentation of previous weight loss attempts
• Diagnosis not covered (weight loss is often excluded)
• Medication not on the plan's formulary
• Step therapy requirement not met (plan requires trying metformin or other medications first)

The denial rate is why many patients turn to compounded semaglutide, which does not go through insurance and therefore does not require prior authorization. The patient pays out of pocket (typically $200 to $400 per month), but receives the medication without the insurance approval process.

Insurance companies impose prior authorization requirements to control costs. Ozempic's wholesale acquisition cost is approximately $935 per month. Insurers argue that prior authorization ensures the medication is prescribed to patients most likely to benefit, reducing unnecessary spending.

Providers argue that prior authorization delays care, creates administrative burden, and denies patients access to effective treatment. The debate continues, but as of 2026, prior authorization remains standard for GLP-1 medications under most commercial and Medicare plans.

When a provider should NOT prescribe Ozempic

The strongest argument against the "everyone who wants Ozempic should get it" narrative is the contraindication list and the patients for whom risk outweighs benefit.

Absolute contraindications (provider must not prescribe):

• Personal history of medullary thyroid carcinoma
• Family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2
• Known severe hypersensitivity to semaglutide or any excipient

Relative contraindications (provider should carefully weigh risk vs benefit):

• Diabetic retinopathy, especially proliferative. The SUSTAIN-6 trial found a 76% relative increase in retinopathy complications (Marso et al., NEJM, 2016). Patients with advanced retinopathy should be monitored by ophthalmology before and during treatment.
• History of pancreatitis. GLP-1 agonists are associated with a small but real increase in pancreatitis risk. Patients with prior pancreatitis are at higher baseline risk.
• Severe gastroparesis. Semaglutide slows gastric emptying, which can worsen pre-existing gastroparesis.
• Eating disorders, especially binge eating disorder or bulimia. The appetite suppression effect can exacerbate disordered eating patterns.
• Pregnancy or planning pregnancy. Semaglutide is Category C (animal studies show risk; no adequate human studies). It should be discontinued at least 2 months before conception.
• Gallbladder disease. Rapid weight loss increases gallstone risk. Patients with symptomatic gallstones should address that before starting semaglutide.

A thoughtful provider also considers patient readiness. Semaglutide is most effective when combined with dietary changes and physical activity. A patient who is unwilling or unable to make those changes is less likely to achieve sustained weight loss and more likely to regain weight after discontinuation.

The decision to prescribe should be individualized, not algorithmic. A 45-year-old with BMI 32, no contraindications, and motivation to change lifestyle is a strong candidate. A 28-year-old with BMI 27, history of eating disorder, and expectation that the medication will work without behavior change is not.

The decision tree: getting a legitimate prescription in 2026

Start here: Do you have a contraindication to semaglutide?

• Personal or family history of medullary thyroid carcinoma → Stop. Semaglutide is contraindicated.
• Multiple endocrine neoplasia syndrome type 2 → Stop. Semaglutide is contraindicated.
• Severe hypersensitivity to semaglutide → Stop. Semaglutide is contraindicated.
• None of the above → Continue.

Do you have a relative contraindication that requires specialist evaluation?

• Active diabetic retinopathy → See ophthalmology before starting semaglutide.
• History of pancreatitis → Discuss risk with provider. Consider alternative.
• Severe gastroparesis → Discuss risk with provider. Consider alternative.
• Active eating disorder → Address eating disorder before starting semaglutide.
• Pregnant or planning pregnancy within 2 months → Delay semaglutide until after pregnancy.
• None of the above → Continue.

Do you meet the clinical indication for semaglutide?

• Type 2 diabetes with inadequate glycemic control → Yes. Proceed to provider consultation.
• BMI ≥ 30 → Yes. Proceed to provider consultation.
• BMI 27-29.9 with weight-related comorbidity (hypertension, dyslipidemia, sleep apnea, cardiovascular disease) → Yes. Proceed to provider consultation.
• None of the above → Discuss with provider whether off-label use is appropriate.

Do you have insurance coverage for Ozempic?

• Yes, and willing to go through prior authorization → Schedule appointment with your primary care provider or endocrinologist. Expect 2-4 week prior authorization process.
• No, or prior authorization was denied → Consider compounded semaglutide via telehealth platform. Out-of-pocket cost typically $200-$400/month.

Choose a prescribing pathway:

• In-person provider: Schedule with primary care, endocrinology, or obesity medicine clinic. Expect 1-2 visits before prescription is written (initial evaluation, then follow-up with lab results).
• Telehealth platform: Complete intake questionnaire, schedule video consultation with licensed provider. If appropriate, prescription is written same day and transmitted to partner pharmacy. Medication ships within 3-5 business days.

After receiving prescription:

• If brand-name Ozempic: Fill at local pharmacy or use manufacturer's mail-order service.
• If compounded semaglutide: Pharmacy ships medication with reconstitution instructions, syringes, and alcohol wipes. Follow reconstitution protocol exactly.
• Schedule follow-up visit in 4 weeks to assess tolerance and adjust dose.
• Expect dose escalation every 4 weeks until reaching maintenance dose or maximum tolerated dose.

FormBlends clinical pattern: what we see in 1,800+ semaglutide consultations

Across 1,800+ initial consultations for compounded semaglutide between January 2024 and March 2026, we see a consistent pattern in the prescription-seeking journey:

The insurance denial pathway is the most common entry point. About 60% of patients who come to FormBlends have already seen their primary care provider, received a prescription for brand-name Ozempic or Wegovy, and had the prior authorization denied by insurance. The denial letter typically cites "not medically necessary" or "step therapy required." These patients are clinically appropriate candidates (BMI ≥ 30 or BMI ≥ 27 with comorbidity), but their insurance plan does not cover GLP-1 medications for weight loss.

The out-of-pocket sticker shock pathway is the second most common. About 25% of patients receive prior authorization approval but discover the copay is $500 to $1,200 per month depending on their plan's specialty tier structure. They turn to compounded semaglutide as a lower-cost alternative.

The direct-to-telehealth pathway represents about 15%. These patients have not seen a provider in person and start their journey with a telehealth platform. They tend to be younger (median age 34 vs 48 for the insurance denial group), more comfortable with digital health, and more likely to be seeking weight loss rather than diabetes management.

The pattern we see most consistently: patients who have done the insurance route first are more adherent to follow-up visits and more realistic about expectations. They have already had the "this is a long-term medication, not a quick fix" conversation with their primary care provider. Patients who start with telehealth are more likely to expect immediate results and more likely to discontinue if they do not see 10+ pounds of weight loss in the first month.

The clinical implication: the prescription requirement serves a gatekeeping function, but the gate is not whether you can access the medication (you can, via multiple pathways). The gate is whether you receive adequate counseling about expectations, risks, and the behavior changes required for success. Platforms that issue prescriptions after a 5-minute questionnaire are technically legal but clinically inadequate.

FAQ

Do you need a prescription for Ozempic in the United States? Yes. Ozempic requires a prescription from a licensed healthcare provider in all 50 states. It is a prescription-only medication under federal law and cannot be purchased over the counter or without a valid prescription.

Can I buy Ozempic online without a prescription? No. Any website offering to sell Ozempic without requiring a prescription is operating illegally. These vendors typically sell counterfeit or contaminated products. Legitimate online pharmacies require a valid prescription before dispensing semaglutide.

Is compounded semaglutide available without a prescription? No. Compounded semaglutide requires a prescription just like brand-name Ozempic. Compounding pharmacies can only prepare semaglutide in response to a patient-specific prescription from a licensed provider.

What type of doctor can prescribe Ozempic? Medical doctors (MD), doctors of osteopathic medicine (DO), nurse practitioners (NP), and physician assistants (PA) can prescribe Ozempic. Endocrinologists, primary care physicians, and obesity medicine specialists are the most common prescribers. Prescribing authority for NPs and PAs varies by state.

Can I get an Ozempic prescription through telehealth? Yes. Telehealth platforms can legally prescribe Ozempic if the provider is licensed in your state and conducts a live video or phone consultation. Prescriptions based solely on a questionnaire without a live consultation may violate state medical practice laws.

How long does it take to get an Ozempic prescription? Through telehealth, you can typically receive a prescription within 24 to 48 hours after your consultation if you are a suitable candidate. Through in-person providers, expect 1 to 2 visits over 2 to 4 weeks, especially if lab work is needed or prior authorization is required.

Do I need a prescription for semaglutide from Canada or Mexico? Yes. Even if you purchase semaglutide from a foreign pharmacy, U.S. Customs requires a valid U.S. prescription to allow the medication into the country. Importing prescription medication without a prescription is illegal under federal law.

Can a pharmacist prescribe Ozempic? Not independently. Pharmacists can initiate or adjust diabetes medications including semaglutide under a collaborative practice agreement with a physician in some states, but this requires a pre-existing protocol and patient-specific authorization. Pharmacists cannot write independent prescriptions for semaglutide.

What happens if I use Ozempic without a prescription? You face legal risk (purchasing prescription medication without a prescription is a misdemeanor in most states), medical risk (no screening for contraindications or monitoring for adverse events), and product quality risk (high likelihood of receiving counterfeit or contaminated medication).

Why does Ozempic require a prescription? Semaglutide requires medical supervision because of its side effect profile, contraindications, and monitoring requirements. It carries a black box warning for thyroid C-cell tumors, has a 0.2% to 0.4% pancreatitis risk, and can cause severe gastrointestinal adverse events. The FDA determined these risks require provider oversight.

Can I get a prescription for Ozempic for weight loss? Yes, but it is off-label use. Ozempic is FDA-approved only for type 2 diabetes. Wegovy (a higher-dose formulation of semaglutide) is FDA-approved for weight loss. Providers can legally prescribe Ozempic off-label for weight loss, but insurance typically will not cover it for that indication.

Does insurance cover Ozempic without a prescription? No. Insurance will not cover any prescription medication without a valid prescription. Additionally, most insurance plans require prior authorization for Ozempic, which requires the prescriber to submit clinical documentation justifying the prescription.

How much does an Ozempic prescription cost without insurance? Brand-name Ozempic costs approximately $935 per month without insurance. Compounded semaglutide costs $200 to $400 per month depending on the provider and pharmacy. The prescription itself (the provider visit) typically costs $50 to $150 for telehealth or is covered by insurance for in-person visits.

Can I use someone else's Ozempic prescription? No. Using a prescription medication prescribed to another person is illegal and dangerous. Semaglutide has contraindications that require individual medical evaluation. Using someone else's medication exposes you to serious health risks and potential legal liability.

What do I need to get an Ozempic prescription? You need a consultation with a licensed provider who will evaluate your medical history, current medications, BMI, and screen for contraindications. For diabetes, you will need recent lab work showing HbA1c levels. For weight loss, you need BMI ≥ 30 or BMI ≥ 27 with a weight-related comorbidity.

Sources

1. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Davies MJ et al. Gastric Emptying and Glycemic Control with Tirzepatide. Diabetes Care. 2023.
5. FDA. Drug Shortage Database: Semaglutide Injection. Updated April 2026.
6. FDA Warning Letter 320-24-15 to Florida Compounding Pharmacy. March 2024.
7. Alliance for Safe Online Pharmacies. Analysis of Counterfeit Semaglutide Products. Drug Testing and Analysis. 2023.
8. Chen L et al. Injection Site Infections from Counterfeit Semaglutide. Clinical Toxicology. 2024.
9. American Medical Association. Prior Authorization Physician Survey. 2024.
10. U.S. Department of Justice. Federal Food, Drug, and Cosmetic Act Section 301(a). 21 U.S.C. § 331.
11. Drug Enforcement Administration. Ryan Haight Online Pharmacy Consumer Protection Act. 2008.
12. American College of Gastroenterology. Guidelines on GERD Management. 2022.
13. National Association of Boards of Pharmacy. State Prescribing Authority Database. 2026.
14. FDA. Ozempic Prescribing Information. Updated January 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.